Clinical trial • Phase III • Other

CEFTRIAXONE SODIUM for Threatened late miscarriage | Threatened abortion antepartum

Phase III trial of CEFTRIAXONE SODIUM for Threatened late miscarriage | Threatened abortion antepartum. Randomised, open-label. 350 participants.

Overview

Trial Therapeutic Area
Other
Trial Disease
Threatened late miscarriage | Threatened abortion antepartum
Trial Stage
Phase III
Drug Modality
Small molecule

Key dates

Initial CTIS Submission Date
13-06-2024
First CTIS Authorization Date
19-09-2024

Trial design

Randomised, open-label Phase III trial in France.

Randomised
Yes
Open Label
Yes
Target Sample Size
350

Eligibility

Recruits 350 Vulnerable population selected (isVulnerablePopulationSelected = true). Trial enrols pregnant women; inclusion requires maternal age >18 years and adequate understanding of French. Protected persons under guardianship/curatorship/legal protection are explicitly excluded. No explicit assent process described; consent is implied to be provided by the adult participant (maternal consent)..

Pregnancy Exclusion
Multiple pregnancies
Vulnerable Population
Vulnerable population selected (isVulnerablePopulationSelected = true). Trial enrols pregnant women; inclusion requires maternal age >18 years and adequate understanding of French. Protected persons under guardianship/curatorship/legal protection are explicitly excluded. No explicit assent process described; consent is implied to be provided by the adult participant (maternal consent).

Inclusion criteria

  • {"criterion_text":"- Threat of late miscarriage with intact membranes between 18 0/7 and 23 6/7 weeks of gestation, defined by transvaginal ultrasound as a cervix ≤10 mm, and/or protrusion of the amniotic sac observed with a speculum.\n- Singleton pregnancy\n- Living fetus at the time of inclusion\n- Maternal age >18 years\n- Absence of regular and painful uterine contractions\n- Adequate understanding of the French language\n- Affiliated with social security"}

Exclusion criteria

  • {"criterion_text":"- Preterm labor defined by regular and painful uterine contractions, and a short cervix\n- Patient under state medical aid (AME) if not exempted from the affiliation requirement\n- Protected person (patient under guardianship/curatorship/legal protection)\n- Multiple pregnancies\n- Premature rupture of membranes\n- Acute chorioamnionitis\n- Contraindication to the antibiotics in the protocol\n- Chromosomal anomaly, congenital malformation\n- Patients who have received antibiotics before inclusion or who require antibiotics for another indication (chorioamnionitis, pyelonephritis, etc.)\n- Participation in another interventional research study or being in the exclusion period following a previous study involving human subjects, if applicable"}

Endpoints

Primary endpoints

  • {"endpoint_text":"- Composite criterion combining late miscarriage, perinatal mortality, and/or severe neonatal morbidity occurring before hospital discharge, including: 1-Late miscarriage","definition_or_measurement_approach":"Composite combining late miscarriage, perinatal mortality and severe neonatal morbidity occurring before hospital discharge (as stated)."}
  • {"endpoint_text":"- Perinatal mortality","definition_or_measurement_approach":""}
  • {"endpoint_text":"- Bronchopulmonary dysplasia","definition_or_measurement_approach":""}
  • {"endpoint_text":"- Sepsis proven by blood culture","definition_or_measurement_approach":"Diagnosis proven by positive blood culture."}
  • {"endpoint_text":"- Intraventricular hemorrhage ≥ Grade 3","definition_or_measurement_approach":""}
  • {"endpoint_text":"- Periventricular leukomalacia ≥ Grade 2","definition_or_measurement_approach":""}
  • {"endpoint_text":"- Necrotizing enterocolitis at stage ≥ 2 according to Bell's classification","definition_or_measurement_approach":"Staging according to Bell's classification (stage ≥2)."}

Secondary endpoints

  • {"endpoint_text":"- Each item of the composite criterion: 1-Neonatal mortality and late miscarriage","definition_or_measurement_approach":""}
  • {"endpoint_text":"- Bronchopulmonary dysplasia according to international recommendations (described by Jobe and Bancalari), diagnosed at discharge or at a corrected age of 36 6/7 weeks of gestation.","definition_or_measurement_approach":"Diagnosis per Jobe and Bancalari criteria at discharge or corrected age 36 6/7 weeks."}
  • {"endpoint_text":"- Sepsis proven by culture, diagnosed by a combination of clinical signs and a positive blood culture","definition_or_measurement_approach":"Diagnosis requires clinical signs plus positive culture (blood culture)."}
  • {"endpoint_text":"- Intraventricular hemorrhage ≥ Grade 3 and/or periventricular leukomalacia, diagnosed by repeated transfontanellar ultrasounds (according to the classification of Vries and Ment)","definition_or_measurement_approach":"Diagnosis by repeated transfontanellar ultrasounds using Vries and Ment classification."}
  • {"endpoint_text":"- Necrotizing enterocolitis ≥ Stage 2, using Bell's classification.","definition_or_measurement_approach":"Staging according to Bell's classification (≥ Stage 2)."}

Recruitment

Planned Sample Size
350
Recruitment Window Months
41
Consent Approach
No detailed informed consent process is provided in the available source. Inclusion criteria require maternal age >18 years and adequate understanding of the French language, indicating consent is to be provided by the adult participant; no assent procedures or multilingual documents are described. Protected persons under legal protection are excluded.

Geography

Total Number Of Sites
13
Total Number Of Participants
350

France

Earliest CTIS Part Ii Submission Date
06-08-2024
Latest Decision Or Authorization Date
19-09-2024
Processing Time Days
44
Number Of Sites
13
Number Of Participants
350

Sites

Site Name
Centre Hospitalier Universitaire De Bordeaux
Department Name
Obstetric gynecology
Contact Person Name
Loic SENTILHES
Contact Person Email
loic.sentilhes@chu-bordeaux.fr
Site Name
Assistance Publique Hopitaux De Paris
Department Name
Obstetric gynecology
Contact Person Name
Dominique LUTON
Contact Person Email
dominique.luton@aphp.fr
Site Name
Assistance Publique Hopitaux De Paris
Department Name
Obstetric gynecology
Contact Person Name
Yves VILLE
Contact Person Email
yves.ville@aphp.fr
Site Name
Les Hopitaux Universitaires De Strasbourg
Department Name
Obstetric gynecology
Contact Person Name
Virginie COLLIN-BUND
Site Name
Centre Hospitalier Intercommunal Creteil
Department Name
Obstetric gynecology
Contact Person Name
Edouard LECARPENTIER
Site Name
Centre Hospitalier Universitaire De Lille
Department Name
Obstetric gynecology
Contact Person Name
Charles GARABEDIAN
Site Name
CHRU De Nancy
Department Name
Obstetric-gynécolgy
Contact Person Name
Olivier MOREL
Contact Person Email
o.morel@chru-nancy.fr
Site Name
Assistance Publique Hopitaux De Paris
Department Name
Obstetric gynecology
Contact Person Name
Camille LE RAY
Contact Person Email
camille.le-ray@aphp.fr
Site Name
Centre Hospitalier Intercommunal De Poissy Saint Germain
Department Name
Obstetric gynecology
Contact Person Name
thibaud QUIBEL
Site Name
Hospices Civils De Lyon
Department Name
O
Contact Person Name
Cyril HUISSOUD
Contact Person Email
cyril.huissoud@chu-lyon.fr
Site Name
Centre Hospitalier Universitaire De Nantes
Department Name
Obstetric gynecology
Contact Person Name
Norbert WINER
Contact Person Email
norbert.winer@chu-nantes.fr
Site Name
Assistance Publique Hopitaux De Paris
Department Name
Obstetric gynecology
Contact Person Name
Lina BEJJANI
Contact Person Email
lina.bejjani@aphp.fr
Site Name
Assistance Publique Hopitaux De Paris
Department Name
Obstetric gynecology
Contact Person Name
Gilles KAYEM
Contact Person Email
gilles.kayem@aphp.fr

Sponsor

Primary sponsor

Full Name
Assistance Publique Hopitaux De Paris
Organisation Type
Hospital/Clinic/Other health care facility
Country Of Registered Address
France

Third parties

  • {"country":"","full_name":"Ministry of Health","duties_or_roles":"Monetary support","organisation_type":""}

Investigational products

Investigational Product Name
CEFTRIAXONE VIATRIS 1 g, poudre pour solution injectable
Active Substance
CEFTRIAXONE SODIUM
Modality
Small molecule
Routes Of Administration
SOLUTION FOR INJECTION
Route
SOLUTION FOR INJECTION
Authorisation Status
Authorised
Starting Dose
1 g
Maximum Dose
1 g
Investigational Product Name
Clarithromycine EG 500 mg comprimés pelliculés
Active Substance
CLARITHROMYCIN
Modality
Small molecule
Routes Of Administration
ORAL
Route
ORAL
Authorisation Status
Authorised
Starting Dose
1.5 g
Maximum Dose
1.5 g
Investigational Product Name
MÉTRONIDAZOLE ARROW 500 mg, comprimé pelliculé sécable
Active Substance
METRONIDAZOLE
Modality
Small molecule
Routes Of Administration
ORAL
Route
ORAL
Authorisation Status
Authorised
Starting Dose
1 g
Maximum Dose
1 g
Combination Treatment
Yes

Related trials

Other published trials that may interest you.